Pharmaceuticals & life sciences publications

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.
Predicting patient health using blockhain and wearable technology

Predicting patient health using blockhain and wearable technology

Wearable technology has taken the world by storm over the past number of years. Members of the public have been liberated, finally able to take control over their health, wellbeing and lifestyle. More so now than ever, lifestyle has become a major factor in the success of many sectors

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

Asia-Pacific Health Industries Newsletter - July 2014

In this edition we highlight recent developments in Asia and Australia including changes in China's compliance and pricing environment, pharmaceutical deals in South Korea and India, digital health, Big Data, and tax developments in Australia, Hong Kong, China and Singapore.

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

Pharma 2020: Supplying the future -- Which path will you take?

PwC's report discusses how pharma companies must develop different supply chain models for different product types and patient segments, use their supply chains for market differentiation and see the role information plays to drive the flow of products and services.

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

Pharma 2020: Taxing times ahead

The fifth report in the series, it focusses on the opportunities and challenges from a tax perspective. It discusses how the political, economic, scientific and social trends currently shaping the commercial environment, together with the development of new, more collaborative business models, will exert increasing pressure on effective tax rates within the industry. It also shows how companies can adapt their strategies to support the provision of outcomes-based healthcare and remain competitive.

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

Pharma 2020: Marketing the future - Which path will you take?

This paper discusses how the industry is no longer being rewarded for incremental innovation, me-too products and selling the most pills. Companies need to add value to patients, and offer a package of products and health services that the market is willing to pay a premium for.

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

Pharma and Life Sciences Tax News - Vol 7, No. 10: IRS Identifies Factors for Determining Deductibility of Settlement Payments

Few tax issues are more fact-intensive than determining the tax consequences to the payor of payments made under a settlement agreement with a governmental body when the agreement is silent as to the nature of the payments. In a legal advice memorandum, the IRS Office of Chief Counsel shed some light on the factors it thinks are important in such a situation. Whenever possible, of course, the taxpayer should seek to negotiate settlement agreement terms that would support the desired tax treatment.

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

Pharma 2020: Virtual R&D

Pharma 2020: Virtual R&D explores how pharma companies could dramatically improve the R&D productivity. It contents that by 2020 the R&D process may be shortened by two-thirds, success rates may dramatically increase, and clinical trial costs could be cut substantially. New computer based technologies will create a greater understanding of the biology of disease and the evolution of ‘Virtual man’ to enable researchers to predict the effects of new drug candidates before they enter human beings.

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

Pharma 2020: The vision: Which path will you take?

But Pharma 2020: The Vision - Which Path Will You Take? indicates that the current pharmaceutical industry business model is both economically unsustainable and operationally incapable of acting quickly enough to produce the types of innovative treatments demanded by global markets. In order to make the most of these future growth opportunities, the industry must fundamentally change the way it operates.

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

Contact us

Mike Swanick
Global Pharma and Life Sciences Leader, PwC US
Tel: +1 (267) 330 6060
Email

Andrew Packman
Global Pharma/LS Tax Leader, PwC UK
Tel: +44 (0)189 552 2104
Email

Peter Kartscher
Global Pharma/LS Assurance Leaser, PwC Israel
Tel: +972 3 795 4410
Email

Follow us